phase readout
saveNCT04933539: Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
ACTIVE_NOT_RECRUITINGupdated 19d ago
community read0 votes
Sponsor: National Cancer Institute (NCI). Phase: PHASE2. Conditions: Multiple Myeloma
view source ↗
comments(0)
5-min edit window · permanent after that